logo
Mass. EMS bills a first step to speed up ambulances and save lives

Mass. EMS bills a first step to speed up ambulances and save lives

Boston Globe25-06-2025
'The EMS system in our state is broken,' Feeley testified Wednesday at a hearing on the Legislature's Joint Committee on Public Health. 'Unfortunately, I witnessed its failures firsthand.'
An EMT at the hearing teared up listening to Feeley's testimony during the hearing that addressed several pending bills related to local public health and emergency services.
Advertisement
Some municipalities, such as Boston, are large enough that they operate their own EMS services. However, around 80 percent of the state's licensed ambulances are operated by private companies that bid for the right to serve each town's population, the Globe
Those private companies have not been able to hire and maintain adequate staff, which has led to ambulance delays, according to the Globe's coverage.
The state also doesn't have a centralized system to coordinate ambulances and send them to another town in case of a shortage.
A slate of bills intends to address the delays, most notably by designating EMS as an
Advertisement
Other legislation would set up a
Other bills discussed at the hearing propose requiring that all 911 dispatchers in the state be trained to instruct people how to do CPR over the phone and creating a database that lists defibrillators across the state.
The bill to make EMS an essential service proposes creating a fund to support EMS agencies and pay for things such as training, equipment, vehicles, and personnel salaries.
Representative Leigh Davis, a Democrat of Great Barrington, who sponsored the bill said that for too long, EMS has been underfunded and is not always covered by patients' insurance.
'In 1973, the federal EMS Act left it up to the states to fund EMS, never recognizing it as an essential service,' Davis said. 'Unlike police and fire, there's no guaranteed funding, just donations, inconsistent local budgets, and low insurance reimbursement rates.'
Mike Woronka, chief executive officer of Action Ambulance, a private company, said that as baby boomers retire, his company has found it difficult to fill EMS positions, making existing employees' jobs harder.
'We are beyond the crisis stage, it is affecting our staff, and it's affecting the residents of this Commonwealth,' Woronka said.
Tina Dixson, an advanced EMT who has worked for 27 years in the Central Massachusetts towns of Hubbardston and Holden said she supports the bill to create a special commission on EMS.
Advertisement
'If you pictured an EMT in a neatly pressed uniform, working … with the calmness and precision of a NASCAR pit crew, but with the bedside manner of Mr. Rogers, that isn't always the case,' Dixson said, 'We need a lot of assistance with some of the things in these bills.'
Dixson also spoke in favor of bills creating a database for defibrillators so that people can locate one close to them in cases of emergency.
Matt Zavadsky, a past president of the National Association of EMTs, said he supports the designation of EMS as an essential service, but noted the bill does not identify a funding source.
Zavadsky said that it would be better for the state to designate EMS an essential service, and require localities to fund operations based on their own needs.
'Should the state set a standard that in rural areas in the Berkshires the response time should be 12 minutes?' Zavadsky said. 'And do they pick the provider they're going to contract with to provide that service? … It [should be] up to the local community to decide that.'
For the bill proposing a pilot program for EMS workers to treat people 'in place,' Zavadsky said there needs to be an emphasis requiring insurers pay for treatment in place as opposed to only covering transportation to a hospital.
'Treatment in place is already proven, there's enough data out there to show that it's safe and it saves money,' he said. 'Payment models drive clinical practice, so we need the bill to require that insurers pay for treatment in place.'
Angela Mathew can be reached at
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Human Osteoblasts Market to Reach US$ 87.1 Million by 2033
Human Osteoblasts Market to Reach US$ 87.1 Million by 2033

Yahoo

time7 hours ago

  • Yahoo

Human Osteoblasts Market to Reach US$ 87.1 Million by 2033

The market is currently experiencing robust growth, fueled by a post-pandemic surge in orthopedic surgeries and significant investment in regenerative medicine. Innovations in 3D bioprinting and smart scaffolds are creating new therapeutic possibilities for bone repair. Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global human osteoblasts market was valued at US$ 48.2 million in 2024 and is expected to reach US$ 87.1 million by 2033 at a CAGR of 6.8% during the forecast period 2025–2033. The future potential of the human osteoblasts market lies in the convergence of artificial intelligence with advanced biomanufacturing. AI-powered platforms are now capable of analyzing genomic data from 1000s of individuals to predict osteoblast response to new drug compounds, drastically reducing discovery timelines. This synergy is enabling the creation of patient-specific 3D-bioprinted bone grafts. As of 2025, researchers are successfully embedding patient-derived osteoblasts into custom scaffolds with 95% cell viability post-printing. These constructs are being tested in preclinical models for craniofacial reconstruction and spinal fusion, promising a new era of personalized regenerative medicine. Demand for highly characterized osteoblasts for these applications is projected to soar. Download Sample Pages: Another significant growth frontier of the human osteoblasts market is the application of osteoblast research to counteract microgravity-induced bone loss in astronauts. With 3 new long-duration space missions planned by international agencies before 2028, research into osteoblast function in simulated microgravity is intensifying. Furthermore, the veterinary orthopedics market represents a substantial, untapped opportunity. In 2024, an estimated 1.2 million companion animals in the U.S. alone underwent procedures for fractures or degenerative joint diseases. The development of canine and equine osteoblast cell lines for testing new veterinary implants and cell-based therapies is an emerging field that could create an entirely new vertical within the broader market. Key Findings in Human Osteoblasts Market Market Forecast (2033) US$ 87.1 million CAGR 6.8% Top Drivers Rising prevalence of osteoporosis and degenerative bone diseases globally. Technological advancements in cell-based therapies and tissue engineering. Increasing geriatric population driving demand for orthopedic surgical procedures. Top Trends Shift towards personalized medicine using patient-derived osteoblast cultures. Development of 3D bioprinting for creating patient-specific bone grafts. Growing adoption of minimally invasive bone regeneration surgical techniques. Top Challenges Expensive cell-based therapies and procedures. Stringent and complex regulatory approval pathways for new biologics. Top 12 Key Players Strategically Dominate the Evolving Global Human Osteoblasts Market The competitive environment is both concentrated and highly specialized. Analysis in 2024 consistently identifies 12 key players shaping the industry. These include Sigma-Aldrich, Athersys Inc., Cerapedics Inc., CryoLife, Inc., and Cytori Therapeutics Inc. Other notable companies are USA Stem Cell Inc., Vericel Corporation, Wright Medical Group N.V, Biocomposites, BD, Zimmer Biomet, and PromoCell. In the crucial U.S. orthopedic biomaterials sector, a key application area, 3 major competitors—Medtronic, DePuy Synthes, and Stryker—were noted as dominant forces in 2024. Suppliers offer highly specific product lines to meet diverse research needs. As of 2025, PromoCell provides 4 primary product categories related to osteoblasts, including cells and specialized growth media. Similarly, Innoprot offers 2 distinct types of primary human osteoblasts as of 2024 Human Calvarial and Human Femoral Osteoblasts in the human osteoblasts market. InSCREENex provides 1 specific immortalized human osteoblast cell line, CI-huOB. Product quality and performance are paramount. Lonza guarantees 10 population doublings for its Clonetics™ Normal Human Osteoblasts, ensuring robust expansion for 2024 research. Innoprot's immortalized cells demonstrate a growth potential of over 30+ passages, a significant advantage. Recent Product and Technology Launches Signal Rapid Advancement Within the Market Innovation remains a cornerstone of human osteoblasts market growth, with companies actively launching advanced products. On April 15, 2024, CryoLife, Inc. introduced 1 new osteoblast culture system designed to enhance cell viability. Zimmer Biomet followed suit in February 2024, launching 1 new bioreactor system for osteoblast cultivation with improved scalability. Innovation extends to cell preservation. In 2024, PromoCell released 1 new protein- and animal component-free cryopreservation medium, Cryo-SFM Plus, featuring advanced antioxidant technology. Intellectual property is also a key competitive tool. Bone Solutions Inc. was awarded 5 new patents in fiscal year 2025 for its Mg OSTEOCRETE technology, a bone substitute that stimulates osteoblast activity. Practical usability is crucial for clinical adoption. Bone Solutions' Mg OSTEOCRETE boasts a preparation time of just 30 seconds, a significant handling benefit for 2025 applications. To support adjacent research fields, PromoCell also launched 1 new Cancer Media Toolbox in 2024 to facilitate the establishment of primary cancer cell lines and complex 3D tumor models. Active Clinical Trials for Osteoblast-Related Therapies Underpin Future Market Expansion The clinical development pipeline is a strong indicator of future commercial opportunities. In February 2024, Biocomposites initiated 2 Phase 2 clinical trials for its STIMULAN VG® bone graft substitute. These trials will assess efficacy in treating diabetic foot osteomyelitis and stage 4 pressure ulcers. Osteosarcoma research, a critical area for the human osteoblasts market, is also advancing. In 2024, the Osteosarcoma Institute (OSI) sponsored 1 Phase 2 clinical trial in Spain for OMO-103, a promising MYC inhibitor. A remarkable 25 months was the fast-tracked timeline to launch the OMO-103 trial, showcasing increased efficiency in clinical development. In the United States, a 2024 study was published on 1 FDA/IRB-approved GMP-manufactured stem cell product, PSC-01, for knee osteoarthritis. The study showed that a single treatment provided pain reduction and increased function for 2.5 years. Research methodologies are also being refined. A 2024 clinical trial enrolled 30 patients to analyze the effects of lasers on alveolar bone preservation. A Phase 1 trial protocol published in 2024 detailed a 3+3 dose escalation method for a study using human umbilical cord-derived osteoblasts for femoral head osteonecrosis. Favorable Regulatory Approvals in 2024 Create a Promising Outlook for Therapies The regulatory climate for cell and gene therapies in the human osteoblasts market became increasingly favorable in 2024. The FDA approved 7 new cell and gene therapy products Amtagvi, Aucatzyl, Beqvez, Kebilidi, Ryoncil, Symvess, and Tecelra. The pace of approvals is accelerating, with 3 of these therapies gaining approval in early 2024 alone. On December 19, 2024, the FDA approved 1 mesenchymal stem cell product, Ryoncil from Mesoblast. Another landmark approval was granted on November 13, 2024, for 1 gene therapy for AADC deficiency, Kebilidi from PTC Therapeutics. On November 8, 2024, the FDA approved 1 CD19-directed T-cell immunotherapy, obecabtagene autoleucel (Aucatzyl), from Autolus Inc. The recommended dose for Aucatzyl is 410x10^6 CAR-positive viable T-cells. StemCyte received approval for 1 allogeneic hematopoietic stem cell therapy, Regenecyte, on November 26, 2024. Patent activity, a precursor to commercialization, is also strong. Innovators at the University of Pittsburgh were issued 5 patents in August 2024, while University of Minnesota researchers secured 111 US patents in 2024 for various health science discoveries. Significant Funding and Strategic Grants Accelerate Osteoblast-Focused Research and Development Robust financial investment is fueling the engine of scientific discovery across the global human osteoblasts market. The Osteosarcoma Institute (OSI) awarded $1,100,000 to 3 groundbreaking osteosarcoma research projects during its 2023–2024 grant cycle. One of these grants provided $500,000 in funding to Dr. David Lyden's team for a project focused on metastasis. The impact of such funding is often magnified. Building on an initial OSI grant, Baylor College of Medicine secured $4,500,000 in additional funding in 2024 to advance CAR-T therapy research. International collaborations are also being funded. In October 2024, one US–Israel Binational Science Foundation grant was awarded to a team including University of Vermont Cancer Center members to study osteosarcoma epigenetics. Wherein, government funding remains critical. In August 2024, Medical College of Georgia scientists received a five-year grant of $2,400,000 from the National Institute on Aging to study how stress hormones signal the skeleton. Philanthropic efforts are also significant, with over $4,600,000 raised from more than 1,000 donations in 2024 to support the OSI's vital mission. Diverse and Critical Applications Are Driving Widespread Adoption Across Multiple Fields The utility of human osteoblasts market extends across a wide spectrum of research and clinical applications. The dynamic interplay between 2 key cell types, osteoblasts and osteoclasts, is central to bone health, driving research into osteoporosis. In the laboratory, standardized protocols are essential. Human osteoblasts from PromoCell require approximately 3 weeks to show detectable mineralization in culture. Advanced 3D modeling is becoming a standard research tool. InSCREENex's immortalized human osteoblasts can form 3D "mini-bones" when cultured under specific conditions. Suppliers like PromoCell target 3 key application areas cell expansion, culture initiation, and differentiation. A 2024 study highlighted the use of 1 new 3D model based on human fetal osteoblasts to study osteocyte commitment. The clinical relevance is clear. The classic period for new bone formation after a tooth extraction, a process driven by osteoblasts, is 6-10 weeks. A 2025 study analyzed ion release from 3D printed scaffolds at 3 days, 7 days, and 15 days, key time points for osteoblast interaction. Quality Guarantees and Emerging Technologies Redefine the Global Human Osteoblasts Market The reliability of research outcomes depends on the quality of the underlying cell products. Suppliers in the market provide stringent quality guarantees. PromoCell guarantees >500,000 viable cells per cryovial after thawing. Innoprot similarly ensures >500,000 viable cells in each vial, cryopreserved at passage one, while Lonza guarantees ≥500,000 viable cells per ampule. For immortalized lines, Innoprot provides >1,000,000 viable cells per vial, and InSCREENex includes >0.5 million viable cells per vial. Longevity in culture is also specified. Innoprot guarantees 15 population doublings for its primary osteoblasts post-delivery. PromoCell recommends a split ratio of 1:3 to 1:6 for its primary cells. To support targeted research, PromoCell holds >100 HLA-typed cell donors in stock as of 2024, offering 4-digit high-resolution typing. The InSCREENex cell line was derived from a 63-year-old female donor. Concurrently, emerging technologies are creating new opportunities for the human osteoblasts market. Three key trends noted in the 2024 orthopedic biomaterials market are biodegradable materials, 3D printing, and nanotechnology. A September 2024 paper detailed 1 study using collagen-based 3D printed scaffolds to investigate osteoblast activity. A May 2024 publication described 1 new 3D in-vitro model using human fetal osteoblasts. A 2025 study utilized 2 cell lines to test 3D printed composite samples, using standards prepared from 1,000 mg/L stock solutions and a plating density of 10,000 cells/well for viability tests. Customize the Data Scope to Match Your Objectives: Strategic Alliances and Focused Regional Developments Indicate Strong Global Market Growth Corporate strategies and regional activities in 2024 and 2025 underscore a commitment to global expansion of the human osteoblasts market. On March 10, 2024, 1 major collaboration was announced between Athersys Inc. and Cerapedics Inc. to develop a novel osteoblast-based therapy. Service providers are also expanding. In 2024, Thermo Fisher launched its "Accelerator™ Drug Development" solutions, offering 360-degree support to biotech companies. Licensing agreements are expanding market access for key biologics. Bio-Thera Solutions entered into 1 exclusive licensing agreement on December 24, 2024, for its ustekinumab biosimilar. On the same day, GlycoNex announced 1 licensing agreement for its denosumab biosimilar, a therapy for bone loss. Regional market activities are intensifying. In 2024, 1 pivotal Phase 2 trial for osteosarcoma was opened in Barcelona, Spain. Stryker expanded with 1 new testing facility in India in February 2024. In May 2024, Sanofi announced 1 new partnership with OpenAI to accelerate R&D. The North American market saw the FDA grant 1 US approval to Pfizer's Beqvez on April 25, 2024. Europe showed activity with 1 approval by the UK's MHRA on January 15, 2025. The Asia-Pacific region is also growing, evidenced by 1 approval in Japan on January 7, 2025, for Biocon's ustekinumab. Global Human Osteoblasts Market Major Players: Athelas Bionova Scientific Cell Signaling Technology Corning EMD Millipore Invitrogen Lonza Merck Group NantKwest Promega R and D Systems ReproCELL Sigma-Aldrich Stemcell Technologies Thermo Fisher Scientific Other Prominent Players Key Market Segmentation: By Product Human Cell Culture Osteoblast Cell Lines By Application Traumatic Injuries Road Accidents Regeneration Surgeries Orthopedics Musculoskeletal and Spine Neurology By End user Hospitals Specialty Clinics Ambulatory Surgical Centers By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034
Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034

Yahoo

time8 hours ago

  • Yahoo

Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034

The global cell dissociation market is valued at USD 461.55 million in 2025 and is projected to reach approximately USD 1,451.89 million by 2034, expanding at a CAGR of 13.58% during the forecast period. Ottawa, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global cell dissociation market size valued at USD 406.36 million in 2024, is projected to reach approximately USD 1,451.89 million by 2034, growing at a CAGR of 13.58%, according to a study by , a sister company of Precedence Research. Widespread application of cell dissociation in diagnostics, study of diseases, isolation of various cell products, etc, due to which the cell dissociation market is progressing. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America led the market share by 38% in 2024. Asia Pacific is expected to be the fastest-growing region in the coming years. By product, the enzymatic dissociation segment dominated the cell dissociation market in 2024. By product, the non-enzymatic dissociation segment is expected to grow at the fastest CAGR during 2025-2034. By type, the tissue dissociation segment held a major share of the market in 2024. By type, the cell detachment segment is expected to witness rapid expansion in the studied years. By end-user, the pharmaceutical & biotechnology companies segment led the cell dissociation market in 2024 and is expected to grow rapidly during the forecast period. Market Overview & Potential The process in which individual cells are separated from a tissue or cell culture, usually for research or therapeutic applications, is known as cell dissociation. Primarily, they are employed in stem cell research, cancer research, tissue engineering, and drug discovery. Currently, the cell dissociation market is experiencing progression in enzymatic and mechanical methods, as well as the involvement of innovative technologies, such as portable electrical devices. Basic use of cell dissociation in the development of regenerative medicine encompasses cell isolation, manipulation, and then reintroduction into the body. Market Scope Metric Details Market Size in 2024 USD 406.36 Million Projected Market Size in 2034 USD 1451.89 Million CAGR (2025 - 2034) 13.58 % Leading Region North America Market Segmentation By Product, By Type, By End-use, By Region Top Key Players Merck KGaA, Thermo Fisher Scientific, Danaher Corp., STEMCELL Technologies, Sartorius AG, BD, Miltenyi Biotec, PAN-Biotech, HiMedia Laboratories, F. Hoffmann-La Roche Ltd., S2 Genomics, Inc. What are the Key Growth Drivers Involved in The Expansion of The Market? Around the world, the developing utilization of cell-based assays in drug discovery and development, as well as in customized medicine, is leading to an increased demand for robust cell dissociation products. The cell dissociation market is further driven by tremendous applications in the escalating demand for cell-based therapies, especially stem cell and gene therapies. Besides this, advancing research techniques, like automation and integration with omics technologies, are supporting process efficiency and further expansion of the market. You can place an order or ask any questions, please feel free to contact us at sales@ What Are the Trends Associated with the Cell Dissociation Market? In 2025, the growing emergence of numerous biotechnology and pharmaceutical industries in research and development is impacting the overall market growth. In July 2025, SPT Labtech, a global company in innovative laboratory automation, collaborated with Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory, to advance automated cell-based assay workflows. In April 2025, EditCo Bio, Inc. and Promega Corporation partnered to empower the era of biologically related cell-based research, such as HiBiT, HaloTag®, and NanoLuc® technologies. In November 2024, Singleron Biotechnologies, a player in single-cell analysis solutions, made a partnership with TOMY Digital Biology Co., Ltd to enable access to Singleron's comprehensive range of single-cell analysis products and services. What Is the Major Limitation in the Market? The cell dissociation market is facing certain challenges, mainly the maintenance of high cell viability and purity after the dissociation process in the production of biopharmaceuticals and cell-based therapies. Besides this, expensive specialized enzymes, automated systems, and other reagents are creating a hindrance to developing cell dissociation technologies. Regional Analysis Become a valued research partner with us - Why did North America Dominate the Cell Dissociation Market in 2024? The market is propelled by immense investments in life sciences research in this region, impacting market development, primarily in the US. Moreover, this region possesses advanced biotechnology and a pharmaceutical industry, and a strong healthcare infrastructure. Along with this, North America's emphasis on the development of precision medicine, 3D cell culture models, and advanced therapies like gene editing is expanding demand for more sophisticated and effective cell dissociation solutions. For instance, In March 2025, RoslinCT and Ayrmid Pharma made a strategic partnership for the production of Omisirge®, a treatment for hematologic malignancies commercialized in the United States by Gamida Cell, a subsidiary of Ayrmid Pharma. In October 2024, FibroBiologics Inc., a clinical-stage biotechnology company, and Charles River Laboratories, a leading drug discovery, development, testing, and manufacturing solutions provider, signed an agreement to develop and manufacture FibroBiologics' therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628. What Made the Asia Pacific Significantly Grow in the Market in 2024? During 2025-2034, the Asia Pacific will expand at the fastest CAGR in the cell dissociation market. Combined factors are impacting the overall market expansion in the ASAP countries, such as China. Japan, India, and South Korea. An expanding healthcare system, with increased focus on R&D, especially in regenerative medicine and stem cell research, is widely involved in the market expansion. Apart from this, ongoing government initiatives to boost the biotechnology domain and accelerate the pipeline in clinical research activities are also propelling the adoption of innovative technologies. For this market, In August 2025, CytoNiche Biotech, a leader in 3D cell production technology, inaugurated its 3D FloTrix™ Experience Hub in Singapore. In July 2025, NKGen Biotech, Inc., a clinical-stage biotechnology company, and Japan-based HekaBio K.K., partnered to expand the regulatory, manufacturing, and commercial development of NKGen's autologous NK cell therapy, troculeucel, in Japan following HekaBio's recently announced investment in common equity of NKGen. Get the latest insights on life science industry segmentation with our Annual Membership: Segmental Insights By product analysis How did the Enzymatic Dissociation Segment Lead the Market in 2024? In 2024, the enzymatic dissociation segment registered dominance in the cell dissociation market. This type of product can give higher cell yield with broader effectiveness at extracting cells from dense or complex tissues as compared to other mechanical methods. Moreover, this approach offers its flexibility in different downstream applications, like flow cytometry, cell sorting, and in vitro assays. Alongside its wide-range utilization in the development of numerous cell-based therapies and its ability to minimize the amount of fibrous connective tissue present in the cell suspension, it boosts further cell viability and downstream analysis in the market. However, the non-enzymatic dissociation segment is predicted to experience rapid growth in the studied years. This product type has several advantages, like it can preserve cell surface proteins, which is vital for downstream assays. Furthermore, non-enzymatic dissociation is favourable for sensitive cells. Also, they are obtained without animal-derived components, making them adaptable for various cell-based therapies is driving overall segment and market expansion. Whereas, non-enzymatic dissociation is greatly employed in isolating and expanding MSCs while protecting their key functional properties. By type analysis Which Type Held the Largest Share of the Cell Dissociation Market in 2024? The tissue dissociation segment dominated the market with a major share in 2024. The segment is driven by rising research in oncology, chronic conditions, and breakthroughs in cell-based therapies. This type mainly contributes to the separation of cells from a tissue sample to create a single-cell suspension, which is further necessary for isolating cells for therapeutic use, research, and diagnostics. Moreover, the cell detachment segment is estimated to grow fastest during 2025-2034. The significance of cell detachments in cell culture, particularly in culturing adherent cells, is increasingly applied in many research and therapeutic applications. Along with this, a rise in demand for monoclonal antibodies in biopharmaceutical and pharmaceutical industries is immensely dependent on cell culture and, consequently, cell detachment techniques. Eventually, they encompass mechanical detachment (scraping or shaking) and physical methods, such as thermal, light, or magnetic manipulation, which can be selected based on the cell type, culture conditions, and downstream applications. By end-user analysis What Made the Pharmaceutical & Biotechnology Companies Segment Dominate in the Market in 2024? The pharmaceutical & biotechnology companies segment was dominant in the cell dissociation market in 2024 and will expand at the fastest CAGR. Widespread use of cell dissociation is seen in these companies, particularly in vaccine development, production of diverse biopharmaceutical products, and cancer research. Additionally, the segment is fueled by the adoption of cell dissociation in drug discovery and development, allowing the generation of single-cell suspensions, which are essential for high-throughput screening of possible drug candidates. The utilization of the single-cell RNA sequencing (scRNA-seq) technique relies on cell dissociation for the analysis of gene expression profiles in individual cells, demonstrating significant insights into drug responses and cellular heterogeneity. Recent Developments in the Cell Dissociation Market In July 2025, AscellaHealth, a leading partner delivering customizable solutions to support the specialty pharmaceutical industry, partnered with Abeona Therapeutics Inc. for pre- and post-launch commercialization of ZEVASKYN™, an FDA-approved cell-based gene therapy. In April 2025, Singleron Biotechnologies launched PythoN i, an advanced tissue having in nuclei extraction and tissue homogenization functions to its tissue processing system. In March 2025, Sphere Bio, a major provider of innovative picodroplet-based microfluidics solutions for functional single-cell analysis and isolation, introduced the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit, the first multiplexed assay developed specifically for the Company's new Cyto-Mine® Chroma platform. In April 2024, Kuraray Co., Ltd. developed PVA (Polyvinyl Alcohol) hydrogel microcarriers for cell cultures used in regenerative medicine. Browse More Insights of Towards Healthcare: The global single-cell sequencing market was valued at US$ 1.63 billion in 2024 and is anticipated to rise to US$ 1.88 billion by 2025. By 2034, the market is projected to exceed US$ 6.65 billion, advancing at a CAGR of 15.05%. The global cellular immunotherapy market reached US$ 11.33 billion in 2024 and is expected to grow to US$ 13.87 billion in 2025, before surging to nearly US$ 85.78 billion by 2034, expanding at a robust CAGR of 22.45% during the forecast period. The global cell and gene therapy clinical trials market was valued at US$ 10.8 billion in 2024, grew to US$ 12.47 billion in 2025, and is projected to achieve US$ 45.31 billion by 2034, registering a CAGR of 15.43% from 2025 to 2034. The global cell-based assays market stood at US$ 17.29 billion in 2024 and is forecast to increase to US$ 18.82 billion in 2025. By 2034, it is anticipated to surpass US$ 39.92 billion, advancing at a CAGR of 8.84%. The global biopharmaceutical contract manufacturing market was calculated at US$ 40.14 billion in 2024, expanded to US$ 44.61 billion in 2025, and is projected to reach approximately US$ 115.65 billion by 2034, growing at a CAGR of 11.14% between 2025 and 2034. The global cell and gene solutions market is on a strong growth trajectory, with revenue expected to scale significantly over the forecast years from 2025 to 2034, potentially reaching into the hundreds of millions. The global cell-based immunotherapies market was valued at US$ 4.59 billion in 2024, is set to grow to US$ 5.28 billion in 2025, and is projected to generate US$ 18.62 billion by 2034, expanding at a CAGR of 15.02% throughout the forecast period. The global cell banking outsourcing market reached US$ 14.37 billion in 2024, expanded to US$ 16.72 billion in 2025, and is forecast to hit US$ 63.49 billion by 2034, growing at a strong CAGR of 16.37%. The global stem cell banking market was valued at US$ 7.85 billion in 2024, grew to US$ 9.12 billion in 2025, and is projected to climb to US$ 35.12 billion by 2034, advancing at a CAGR of 16.14% between 2025 and 2034. The global host cell protein testing market stood at US$ 2.37 billion in 2024, increased to US$ 2.56 billion in 2025, and is projected to cross US$ 5.19 billion by 2034, expanding at a CAGR of 8.17%. The global stem cell assay market was valued at US$ 2.68 billion in 2024, grew to US$ 3.15 billion in 2025, and is expected to achieve US$ 13.5 billion by 2034, rising at a significant CAGR of 17.55%. The global live cell imaging market reached US$ 2.92 billion in 2024, expanded to US$ 3.16 billion in 2025, and is anticipated to generate US$ 6.49 billion by 2034, progressing at a CAGR of 8.34%. The global immortalized cell line market was valued at US$ 4.55 billion in 2024, increased to US$ 4.85 billion in 2025, and is projected to attain US$ 8.68 billion by 2034, advancing at a CAGR of 6.71%. The global cell viability assays market stood at US$ 1.89 billion in 2024, grew to US$ 2.05 billion in 2025, and is projected to reach US$ 4.24 billion by 2034, expanding at a CAGR of 8.54%. The global stem cell reconstructive market was valued at US$ 1.56 billion in 2024, is forecast to grow to US$ 1.88 billion in 2025, and is expected to achieve US$ 10.32 billion by 2034, advancing at an impressive CAGR of 20.81%. Cell Dissociation Market Key Players Merck KGaA Thermo Fisher Scientific Danaher Corp. STEMCELL Technologies Sartorius AG BD Miltenyi Biotec PAN-Biotech HiMedia Laboratories F. Hoffmann-La Roche Ltd. S2 Genomics, Inc. Segments Covered in The Report By Product Enzymatic Dissociation Trypsin Collagenase Elastase Papain Hyaluronidase DNase Others Non-enzymatic dissociation Instruments & Accessories By Type Tissue Dissociation Cell Detachment By End-use Pharmaceutical & Biotechnology Companies Research & Academic Institutes By Region North America U.S. Canada Mexico Europe Germany UK Spain Italy France Denmark Norway Sweden Asia Pacific Japan China India Australia Thailand South Korea Latin America Brazil Argentina MEA South Africa Saudi Arabia UAE Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region: +44 778 256 0738 North America Region: +1 8044 4193 44 Web: Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | PinterestError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Vitamin Supplements Market Size to Capture USD 113.93 Billion by 2034, Driven by Growing Health Awareness, Innovative Product Forms and AI Integration
Vitamin Supplements Market Size to Capture USD 113.93 Billion by 2034, Driven by Growing Health Awareness, Innovative Product Forms and AI Integration

Yahoo

time9 hours ago

  • Yahoo

Vitamin Supplements Market Size to Capture USD 113.93 Billion by 2034, Driven by Growing Health Awareness, Innovative Product Forms and AI Integration

According to Towards FnB, the global vitamin supplements market size is evaluated at USD 59.92 billion in 2025 and is predicted to hit around USD 113.93 billion by 2034, growing at a CAGR of 7.4% during the forecast period from 2025 to 2034. Ottawa, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global vitamin supplements market size stood at USD 55.79 billion in 2024 and is expected to grow steadily form USD 59.92 billion in 2025 to around USD 113.93 billion by 2034, expanding at a CAGR of 7.4% from 2025 to 2034, according to study published by Towards FnB, a sister firm of Precedence Research. The market has experienced significant growth in recent years, largely due to the rapid prevalence of diseases affecting a substantial portion of the population. An increasing health-conscious attitude among people of different age groups, along with rising awareness about health and nutrition, are also growth factors for the market. Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making. Access the Full Study Instantly | Download Sample Pages of the Report Now@ Market Overview The vitamin supplements market is observing a huge hike in the recent period due to the developing health-conscious attitude among the population of different age groups. Vitamin supplements help consumers to complete their nutritional requirements easily, which might be missed from the regular diet. Such supplements are focused on providing the nutrition required in an ideal quantity, making it easy for an individual to measure the quantities as per their health. Innovation in the supplements market has made it easy for kids to consume vitamin supplements. They are available in gummy form and in different flavors to make it easy for kids to maintain their nutritional requirements. Adults also enjoy such a form of supplements and do not miss out on their gummies, helping them to maintain their nutritional requirements and keeping deficiencies at bay. It helps consumers to avoid various health issues caused by vitamin deficiency, such as skin and hair issues, overall health, cell repair and growth, and immune function. Consumer preferences are shifting, particularly among millennials and Gen Z, who are prioritizing natural and plant-based supplements. A significant portion of these consumers is leaning toward gummy supplements, as they are perceived as more enjoyable and easier to incorporate into daily routines. Additionally, vegan vitamin supplements are seeing increased demand due to the rise in plant-based diets. Key Highlights of the Vitamin Supplements Market By region, North America dominated the vitamin supplements market in 2024, whereas the Asia Pacific is expected to grow in the foreseeable period due to the growing population's health management and the need to keep the aging population healthy. By form, the tablet segment led the market for vitamin supplements in 2024, whereas the gummies segment is expected to grow in the foreseen period due to its convenience factor and availability of flavors, making it easy for kids to consume. By type, the multivitamin segment led the vitamin supplements market in 2024, whereas the vitamin D segment is expected to grow due to the rising prevalence of cardiovascular diseases among the population of different age groups. By distribution channel, the offline segment led the vitamin supplements market in 2024, whereas the online segment is expected to grow in the foreseen period due to the rise of online platforms, due to its multiple benefits, and providing a knowledge factor. New Trends in the Vitamin Supplements Market High demand for recovery supplements has been observed in the recent period, as such supplements help in quick recovery after exercising. They are made up of ingredients like electrolytes for hydration, protein for muscle repair, and various other essential nutrients that help replenish energy and lower soreness after a heavy training session. Collagen supplements are another highly demanded supplement in the market as they support hair, nail, and skin health. Hence, the beauty trends help the sale of the product, further helping the growth of the vitamin supplements market. Magnesium is another vitamin supplement highly demanded in the market these days, as it aids in natural sleep. It helps to aid rest for the body, helpful for muscle repair. The vitamin supplements market is also experiencing growth due to government initiatives, NGO initiatives, and educating people about the importance of vitamin supplements. How Has AI Impacted the Vitamin Supplements Market? Artificial intelligence (AI) is reshaping the vitamin supplements market by driving innovation, personalization, and efficiency across the value chain. One of the most notable benefits is the ability of AI to analyze massive datasets on consumer health profiles, genetic information, and lifestyle patterns to create personalized supplement recommendations. This has fueled the rise of customized vitamin packs and subscription models tailored to individual nutritional needs. AI also accelerates research and development by simulating ingredient interactions, predicting efficacy, and identifying emerging health trends, enabling faster launches of new and targeted formulations. In manufacturing, AI-powered quality control systems ensure consistency and safety by detecting impurities or variations in raw materials and finished supplements. Marketing strategies have become more precise as AI-driven tools leverage customer behavior analytics and social media sentiment to design targeted campaigns that resonate with different age groups and health-conscious consumers. Recent Developments in the Vitamin Supplements Market In April 2025, Vitamin Shoppe launched its GLP-1-inspired line of supplements to aid natural weight loss. The line consists of meal replacement powder, fiber supplements, and a multivitamin supplement. (Source- In July 2025, Vegamour launched its vegan haircare and hair growth supplements. The supplements combine vitamins, minerals, and adaptogens essential for hair growth and strengthen the hair locks. (Source- View Full Market Intelligence@ Market Dynamics What are Major Drivers for Vitamin Supplements Market? Multiple health factors have helped the growth of the vitamin supplements market in the recent period. Growing awareness of health and overall fitness, and a health-conscious attitude among people, have helped the growth of the vitamin supplements market. The increasing prevalence of different types of diseases also helps the growth of the market in the form of high demand for vitamin supplements. Growing consciousness for hair, skin, and nail health is also leading to demand for collagen supplements, further boosting the growth of the vitamin supplements market. A busy lifestyle leading to improper nutrition and an incomplete diet is also helping the growth of the market, as supplements help to recover the nutritional deficiencies. What Factors Create Limitations for Vitamin Supplements Market? High demand for different types of vitamin supplements by different age groups is one of the major challenges observed in the growth of the vitamin supplements market. If the supply is inadequate as per the demand, then the population may miss out on their supplements, lowering the market's growth. Supply chain disruptions due to multiple reasons are also a major reason affecting the growth of the market. What is the Largest Potential Factor for Vitamin Supplements Market? Innovation in vitamin supplements is helping the growth of the vitamin supplements market, as consumers are highly demanding such supplements. Vitamins are essential for overall health and are also an essential part of maintaining beauty features such as hair, skin, and nail health. Hence, such factors also help the growth of the market. Availability of vitamin supplements in plant-based forms for vegans and plant-diet followers is also helping the growth of the market. Gummies and flavored vitamin supplements are also aiding the growth of the market in the foreseeable period. Vitamin Supplements Market Regional Analysis North America dominated the Vitamin Supplements Market in 2024 North America led the vitamin supplements market in 2024 due to rising awareness about health and nutrition, and overall well-being in the region. Consumers in the region are conscious about the overall well-being and importance of vitamin supplements for the same. High demand for vitamin D, vitamin C, multivitamins, zinc, and collagen supplements has also helped the growth of the vitamin supplements market in the region. High demand for organic and plant-based supplements has also helped the growth of the market. Canada has a huge contribution to the growth of the market in the region, with high demand for vitamin D supplements for its multiple benefits and overall health benefits too. Asia Pacific Is expected to Grow with the Highest CAGR in the Forecast Period Asia Pacific is expected to grow with the highest CAGR in the forecast period due to the rising aging population in the region. Vitamin supplements are helpful for maintaining overall health and completing the nutritional requirements that might not be fulfilled with a basic diet. Hence, such supplements are essential for growing kids and aged adults to complete their nutritional requirements. Countries like China, Japan, and South Korea have the highest contribution to the growth of the market due to the rising aging population of the region. Vitamin Supplements Market Report Scope Report Attribute Key Statistics Base Year 2024 Forecast Period 2025 to 2034 Growth Rate from 2025 to 2034 CAGR of 7.4% Market Size in 2024 USD 55.79 Billion Market Size in 2025 USD 59.92 Billion Market Size by 2034 USD 113.93 Billion Dominated Region North America Fastest Growing Region Asia Pacific Regions Covered North America, Europe, Asia-Pacific, Latin America and Middle East & Africa Have Questions? Let's Talk—Schedule a Meeting with Our Insights Team: Vitamin Supplements Market Segmental Analysis Form Analysis Why Did the Tablet Segment Lead the Vitamin Supplements Market in 2024? The tablet segment led the vitamin supplements market in 2024 due to its convenience factor and multiple health benefits for the human body. Tablets are easy to consume, have a longer shelf life, and are also easy to carry while travelling, so that one doesn't miss out on essential nutrients while being outdoors. Tablets available in different coatings, as per the preference of each individual, also help the growth of the vitamin supplements market. Gummies and slow-release tablets for their full-day effect also help the growth of the market. The Gummies Segment is Expected to Grow in the Forecast Period Gummy vitamins are expected to grow in the foreseeable period due to their multiple health benefits available in different flavor options. Due to the innovation and availability in chewy texture and different flavors, kids easily consume such nutritional gummies. It helps them to maintain their nutritional requirements. Adults can also consume vitamin gummies to complete their nutritional requirements and avoid deficiencies, further fueling the growth of the vitamin supplements market. It is, though, advised to keep a check on the consumption of vitamins such as calcium, iron, vitamin D, and vitamin A, as their high consumption is harmful to health. Type Analysis Why Did the Multivitamin Segment Lead the Vitamin Supplements Market in 2024? The multivitamin segment led the vitamin supplements market in 2024 due to its importance and high consumption globally, as it helps in aiding overall health. The multivitamins are essential for people of different age groups and their overall well-being. Hence, their high consumption at the global level helped the growth of the market in 2024. Vitamin C, vitamin D, and zinc top the list of essential nutrients and hence are highly demanded, further fueling the growth of the market. The Vitamin D Segment Is Observed to Grow in the Foreseen Period High demand for vitamin D these days, for its multiple health benefits, is helping the growth of the vitamin supplements market in the foreseeable future. Vitamin D, along with calcium, helps build bone health and keep the bones healthy. The nutrient also helps to maintain immunity, along with maintaining muscles and brain cells. Distribution Channel Analysis How Did the Offline Segment Lead the Vitamin Supplements Market in 2024? The offline segment led the vitamin supplements market in 2024 due to its convenience factor, allowing consumers to shop for the required supplements easily and refill them as well. The segment also helped the growth of the market by providing different types of supplements along with beauty supplements and treatments, alongside further fueling the beauty trends and market growth. The Online Segment is Expected to Grow in the Expected Timeframe The online segment is observed to grow in the foreseen period due to its high demand from the convenience and knowledge point of view. The E-pharmacy option is extremely beneficial for seniors, the disabled, and consumers living in remote areas who might face issues in visiting pharmacies physically. Online pharmacies also provide discounts on certain occasions, making the supplement shopping more economical. Hence, the segment is observed to fuel the growth of the vitamin supplements market in the foreseeable period. Feel Free to Get in Touch with Us for Orders or Any Questions at: sales@ Additional Topics Worth Exploring: Infant Nutrition Market: The global infant nutrition market size is set for steady growth increasing from USD 60.13 billion in 2025 to USD 144.11 billion by 2034, with a CAGR of 10.2% during the forecast period from 2025 to 2034. Infant Formula Ingredient Market: The global infant formula ingredient market size increasing from USD 25.01 billion in 2025 to USD 57.07 billion by 2034, driven by a CAGR of 9.60% during the forecast period from 2025 to 2034. Food Leavening Agent Market: The global food leavening agent market size is projected to witness strong growth from USD 7.64 billion in 2025 to USD 11.06 billion by 2034, reflecting a CAGR of 4.2% over the forecast period from 2025 to 2034. Food Texture Market: The global food texture market size is increasing from USD 16.67 billion in 2025 to USD 27.22 billion by 2034, driven by a CAGR of 5.6% during the forecast period from 2025 to 2034. Food Intolerance Products Market: The global food intolerance products market size is projected to grow from USD 97.47 billion in 2025 to USD 302.26 billion by 2034, reflecting a CAGR of 13.40% over the forecast period from 2025 to 2034. Superfoods Market: The global superfoods market size is expected to grow from USD 201.17 billion in 2025 to USD 288.82 billion by 2034, at a CAGR of 4.10% during the forecast period from 2025 to 2034. Probiotics Animal Feed Market: The global probiotics animal feed market size was estimated at USD 4.99 billion in 2024 and is expected to rise from USD 5.44 billion in 2025 to nearly reaching USD 11.72 billion by 2034, growing at a CAGR of 8.86% during the forecast period from 2025 to 2034. Feed Phosphate Market: The global feed phosphate market size is rising from USD 2.82 billion in 2025 to USD 4.75 billion by 2034. This projected expansion reflects a CAGR of 5.96% throughout the forecast period from 2025 to 2034. Textured Vegetable Protein Market: The global textured vegetable protein market size is expected to grow from USD 1.92 billion in 2025 to USD 3.48 billion by 2034, at a CAGR of 6.97% over the forecast period from 2025 to 2034. Organic Pet Food Market: The global organic pet food market size is projected to expand from USD 2.54 billion in 2025 to USD 4.41 billion by 2034, growing at a CAGR of 6.34% during the forecast period from 2025 to 2034. Key Players in Vitamin Supplements Market Nordic Naturals NOW Foods Abbott Amway Doctor's Best Inc Biophar Lifesciences Pvt Ltd Ritual Garden of Life Nestle Health Sciences Pharmavite Thorne Aesthetic Nutrition Arlak Biotech Pvt Ltd Gianful HealthAid Jarrow Formulas Segments Covered in the Report By Type Multivitamin Vitamin A Vitamin B Vitamin C Vitamin D Vitamin E Vitamin K By Form Powder Tablets Capsules Softgels Gummies Others By Distribution Channel Offline Pharmacies & Drugstores Hypermarkets/Supermarkets Others Online By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Thank you for exploring our insights. For more targeted information, customized chapter-wise sections and region-specific editions such as North America, Europe, or Asia Pacific are also available upon request. For Detailed Pricing and Tailored Market Report Options, Click Here: Feel Free to Get in Touch with Us for Orders or Any Questions at: sales@ Unlock expert insights, custom research, and premium support with the Towards FnB Annual Membership. For USD 495/month (billed annually), get full access to exclusive F&B market data and personalized guidance. It's your strategic edge in the food and beverage industry: About Us Towards FnB is a global consulting firm specializing in the food and beverage industry, providing innovative solutions and expert guidance to elevate businesses. With an in-depth understanding of the dynamic F&B sector, we deliver customized market analysis and strategic insights. Our team of seasoned professionals is committed to empowering clients with the knowledge needed to make informed decisions, ensuring they stay ahead of market trends. Partner with us as we redefine success in the rapidly evolving food and beverage landscape, and together, we'll navigate this transformative journey. Web: Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Chemical and Materials| Nova One Advisor | Food Beverage Strategies | For Latest Update Follow Us: LinkedIn | Medium| TwitterError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store